CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Regulation FD Disclosure
Item 7.01
On September 9, 2019, we are posting an investor presentation to our website (www.chembio.com). A copy of this investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8‑K and is incorporated herein by reference.
The information contained herein, including the exhibit furnished hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such filing.
CHEMBIO DIAGNOSTICS, INC. Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate PresentationSeptember 2019 © 2018 Chembio. All Rights Reserved. | # © 2019 Chembio. All Rights Reserved. Page 1 Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,…
To view the full exhibit click
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate PresentationSeptember 2019 © 2018 Chembio. All Rights Reserved. | # © 2019 Chembio. All Rights Reserved. Page 1 Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,…
To view the full exhibit click
hereAbout CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
An ad to help with our costs
